<DOC>
	<DOCNO>NCT00587769</DOCNO>
	<brief_summary>The overarch goal line research increase smoking abstinence rate use combination exist pharmacotherapies . The aim current study ass safety compliance well obtain preliminary estimate efficacy effect crave nicotine withdrawal combination therapy bupropion SR varenicline . We compare efficacy estimate study historical smoking abstinence rate varenicline . To accomplish aim , enroll 38 cigarette smoker open-label , phase II clinical trial .</brief_summary>
	<brief_title>Chantix &amp; Bupropion Smoking Cessation</brief_title>
	<detailed_description>Subjects eligible participate : 1 ) least 18 year age ; 2 ) smoke 10 cigarette per day least 6 month ; 3 ) motivate stop smoking . Subjects exclude : 1 ) unstable medical condition ; 2 ) unstable angina , myocardial infarction , coronary angioplasty within past 3 month untreated cardiac dysrhythmia ; 3 ) personal history seizure ; 4 ) close head trauma loss consciousness amnesia last 5 year ; 5 ) ever history close head trauma &gt; 30 minute loss consciousness amnesia result skull fracture subdural hematoma/brain contusion ; 6 ) history psychosis , bipolar disorder , bulimia anorexia nervosa ) ; 7 ) current depression assess Center Epidemiologic Studies Depression ( CES-D ) ; 8 ) active substance abuse nicotine ; 9 ) use investigational drug within last 30 day ; 10 ) currently use behavioral pharmacologic tobacco treatment unwilling unable discontinue use ; 11 ) use bupropion varenicline previous 3 month ; 12 ) current ( past 14 day ) use antipsychotic antidepressant ; 13 ) allergy bupropion varenicline ; 14 ) untreated hypertension baseline systolic blood pressure &gt; 180 diastolic &gt; 100 ; 15 ) another member household already participate study . The primary aim hypothesis study : 1 . To obtain preliminary evidence efficacy 12 week combination therapy bupropion SR varenicline increase point prevalence smoking abstinence rate 12 week among cigarette smoker . Hypothesis : The combination bupropion SR plus varenicline 12 week increase point prevalence smoking abstinence rate 12 week among cigarette smoker . 2 . To obtain preliminary evidence efficacy combination therapy bupropion SR varenicline decrease crave nicotine withdrawal symptom among cigarette smoker try achieve smoke abstinence . Hypothesis : 12 week combination therapy bupropion SR varenicline significantly decrease crave nicotine withdrawal among cigarette smoker try achieve smoke abstinence .</detailed_description>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>least 18 year age smoke 10 cigarette per day least 6 month motivate stop smoking . unstable medical condition unstable angina , myocardial infarction , coronary angioplasty within past 3 month untreated cardiac dysrhythmia personal history seizure close head trauma loss consciousness amnesia last 5 year ever history close head trauma &gt; 30 minute loss consciousness amnesia result skull fracture subdural hematoma/brain contusion history psychosis , bipolar disorder , bulimia anorexia nervosa ) current depression assess Center Epidemiologic Studies Depression ( CESD ) active substance abuse nicotine use investigational drug within last 30 day currently use behavioral pharmacologic tobacco treatment unwilling unable discontinue use use bupropion varenicline previous 3 month current ( past 14 day ) use antipsychotic antidepressant allergy bupropion varenicline untreated hypertension baseline systolic blood pressure &gt; 180 diastolic &gt; 100 another member household already participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Smoking</keyword>
	<keyword>Smoking cessation</keyword>
	<keyword>Bupropion</keyword>
	<keyword>Varenicline</keyword>
	<keyword>Tobacco use disorder</keyword>
</DOC>